Novel Long Noncoding RNAs, LINC01093 and MYLK-AS1, Serve as Potential Diagnostic and Prognostic Biomarkers or Hepatocellular Carcinoma.

IF 2.6 4区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY DNA and cell biology Pub Date : 2023-08-01 DOI:10.1089/dna.2022.0566

Yanming Qin, Xin Tu, Meifang Huang, Caifang Ma, Qiongqing Huang, Qiqi Huang, Hong Shu, Chao Ou

{"title":"Novel Long Noncoding RNAs, LINC01093 and MYLK-AS1, Serve as Potential Diagnostic and Prognostic Biomarkers or Hepatocellular Carcinoma.","authors":"Yanming Qin, Xin Tu, Meifang Huang, Caifang Ma, Qiongqing Huang, Qiqi Huang, Hong Shu, Chao Ou","doi":"10.1089/dna.2022.0566","DOIUrl":null,"url":null,"abstract":"Hepatocellular carcinoma (HCC) is one of the most fatal human malignancies worldwide. In this research, we aimed to identify long noncoding RNAs (lncRNAs) as biomarkers for HCC diagnosis and prognosis. lncRNA expression profiles were obtained from Gene Expression Omnibus and The Cancer Genome Atlas databases. The differentially expressed lncRNAs between HCC and adjacent tissues were analyzed with bioinformatic tools. Four lncRNAs with area under the curve of the receiver operating characteristic curve >0.9 were selected from both datasets. Univariate and Kaplan-Meier analyses were performed to obtain LINC01093, MYLK-AS1, and MCM3AP-AS1 as the optimal diagnostic and prognostic biomarkers. Finally, qPCR confirmed that LINC01093 and MYLK-AS1 were significantly differentially expressed in HCC and adjacent normal tissues. In general, we demonstrated that novel lncRNAs, LINC01093 and MYLK-AS1, could be used as potential diagnostic and prognostic biomarkers for HCC.","PeriodicalId":11248,"journal":{"name":"DNA and cell biology","volume":"42 8","pages":"488-497"},"PeriodicalIF":2.6000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"DNA and cell biology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1089/dna.2022.0566","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Hepatocellular carcinoma (HCC) is one of the most fatal human malignancies worldwide. In this research, we aimed to identify long noncoding RNAs (lncRNAs) as biomarkers for HCC diagnosis and prognosis. lncRNA expression profiles were obtained from Gene Expression Omnibus and The Cancer Genome Atlas databases. The differentially expressed lncRNAs between HCC and adjacent tissues were analyzed with bioinformatic tools. Four lncRNAs with area under the curve of the receiver operating characteristic curve >0.9 were selected from both datasets. Univariate and Kaplan-Meier analyses were performed to obtain LINC01093, MYLK-AS1, and MCM3AP-AS1 as the optimal diagnostic and prognostic biomarkers. Finally, qPCR confirmed that LINC01093 and MYLK-AS1 were significantly differentially expressed in HCC and adjacent normal tissues. In general, we demonstrated that novel lncRNAs, LINC01093 and MYLK-AS1, could be used as potential diagnostic and prognostic biomarkers for HCC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

新型长链非编码rna LINC01093和MYLK-AS1可作为肝细胞癌的潜在诊断和预后生物标志物

肝细胞癌(HCC)是世界上最致命的人类恶性肿瘤之一。在本研究中，我们旨在鉴定长链非编码rna (lncRNAs)作为HCC诊断和预后的生物标志物。lncRNA表达谱从Gene expression Omnibus和The Cancer Genome Atlas数据库中获得。利用生物信息学工具分析HCC与邻近组织之间lncrna的差异表达。从两个数据集中选择4个接受者工作特征曲线下面积>0.9的lncrna。通过单因素分析和Kaplan-Meier分析，获得LINC01093、mylar - as1和MCM3AP-AS1作为最佳诊断和预后生物标志物。最后，qPCR证实了LINC01093和MYLK-AS1在HCC和邻近正常组织中的表达存在显著差异。总的来说，我们证明了新的lncrna, LINC01093和MYLK-AS1，可以用作HCC的潜在诊断和预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

DNA and cell biology 生物-生化与分子生物学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

1.5 months

期刊介绍： DNA and Cell Biology delivers authoritative, peer-reviewed research on all aspects of molecular and cellular biology, with a unique focus on combining mechanistic and clinical studies to drive the field forward. DNA and Cell Biology coverage includes: Gene Structure, Function, and Regulation Gene regulation Molecular mechanisms of cell activation Mechanisms of transcriptional, translational, or epigenetic control of gene expression Molecular Medicine Molecular pathogenesis Genetic approaches to cancer and autoimmune diseases Translational studies in cell and molecular biology Cellular Organelles Autophagy Apoptosis P bodies Peroxisosomes Protein Biosynthesis and Degradation Regulation of protein synthesis Post-translational modifications Control of degradation Cell-Autonomous Inflammation and Host Cell Response to Infection Responses to cytokines and other physiological mediators Evasive pathways of pathogens.